Biomarkers in Prostate Cancer
Ingrid Bowser, MS, APRN-BC, AOCNP®, ADM-BC, and
Kristan Rheinheimer, MSN, FNP-BC, AOCNP®
From Goshen Center for Cancer Care, Goshen, Indiana
The authors have no potential conflicts of interest to disclose.
Correspondence to: Ingrid Bowser, MS, APRN-BC, AOCNP®, ADM-BC, Goshen Center for Cancer Care, 200 High Park Avenue, Goshen, IN 46526. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2011;2:37–45 |
DOI: 10.6004/jadpro.2011.2.1.4 |
© 2011 Harborside Press®
Prostate cancer represents the most common noncutaneous cancer in men in the United States. Although PSA testing with or without digital exam has led to increased prostate cancer detection, it continues to lack specificity, which leads to the inability to predict which men will benefit from biopsy and/or prostate cancer treatment. The lack of specificity has led to varying screening recommendation from multiple organizations. Patients are also questioning the benefit of PSA screening. This article reviews the history of prostate cancer and PSA screening, discusses the current controversy in PSA screening, and provides guidelines for the role the advanced practitioner in patient selection and counseling. The continual controversy has led to more interest in pursuing more accurate predictors of prostate cancer. A discussion of emerging biomarkers, PCA3, and the TMPRSS2:ERG gene is also included.
For access to the full length article, please sign in